CV Therapeutics Shares Fall on Downgrade

By Joseph Major
28 March 2007 @ 06:35 pm EDT

Shares of CV Therapeutics Inc.(Nasdaq: CVTX) fell on Wednesday, after Citigroup downgraded the firm.

CV Therapeutics fell 67 cents,the or 8.42 percent, to $7.29 after the rating on stock was cut to 'sell' from 'hold.'

Citigroup analyst Dr. Yaron Werber lowered the firm's price target to $6 from $15, stating that he saw diminished market potential for Ranexa, a drug already approved to treat chronic angina. A study involving the drug this week showed that Ranexa did not meet its goals.

He also noted that the company has high operating costs and is in need of additional financing. He stated that finding the funds could be difficult based on the Ranexa results and the current amount of debt at the firm.

This article is copyrighted by International Business Times.

E-Newsletters

We value your privacy. Your email address will not be shared.

Home
World
US
Economy
Companies
Tech
Science
Global Markets
Education
Real Estate
Forex
Commodities
Gold & Silver Matters
More Sections
Fashion
Auto
Travel
Health
Law
Entertainment
Sports
Luxury
Art
Books
Tech & Trend
Tools & Features
Topics
Blogs
Market Data
Stock Watch List
Investment Calculator
Financial Glossary
Broker Center
World Business Headlines
Updates
RSS Feeds
IBTimes on Twitter
IBTimes on Facebook
E-Newsletters
Services
Forex Newsfeed
Research
Press Release
About IBTimes
News Licensing
Media Kit
Advertise with Us
About IBTimes
Contact Us
Terms of Service
Privacy Policy